Humana Rebounds in Medicare Advantage Star Ratings for 2027
Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.
How this was made
The 30-second read
Why it matters
Humana’s regained 4-star rating and higher 4-star enrollment materially improve the expected Medicare Advantage bonus revenue profile for 2028, while Alignment’s contract falling below the 4-star threshold creates a clear revenue downside and increases uncertainty due to its stated intent to pursue administrative remedies and litigate.
Market read
This is a direct, company-specific read-through from CMS star ratings to Medicare Advantage bonus revenue expectations, with immediate after-hours equity reactions for HUM and ALHC.
What to watch
The article notes CMS methodology changes (added measures, adjusted weights, higher thresholds). Traders should separate the mechanical bonus impact from whether improved ratings persist into subsequent years and whether litigation or administrative remedies can alter outcomes for ALHC.
Background
CMS Medicare Advantage star ratings determine bonus payments and other financial benefits, and CMS changed the methodology for 2027 by adding measures, adjusting weights, and raising performance thresholds.
Ticker impact
Humana’s share of Medicare Advantage members in 4-star-or-higher plans for 2027 jumps to 93% from 41% in 2026 after CMS quality data release.
Likely upward bias as the market prices in higher 2028 bonus revenue tied to the regained 4-star rating.
The article cites a large improvement in 4-star enrollment and a specific analyst estimate of $3B+ additional 2028 revenue, plus a near-term after-hours stock pop.
Alignment Healthcare’s largest Medicare Advantage contract drops below the 4-star threshold for 2027, leaving only 25% of members above that level next year.
Likely downside pressure as investors price in reduced 2028 revenue and uncertainty from the company’s stated intent to litigate.
The article provides a member-weighted threshold drop and a revenue loss estimate of more than $170M in 2028, alongside a >20% share decline after the ratings were released.
Clover Health received a top 5-star Medicare Advantage contract for 2027 after previously challenging CMS calculations.
Mild-to-moderate positive bias as investors may re-rate the likelihood of sustained high-star outcomes.
The article confirms a 5-star contract and includes CEO commentary, but does not quantify incremental revenue or provide a same-day price reaction for CLOV.
Market effects
CMS methodology changes and the lower average star rating (3.99 vs 4.01) can reset expectations for Medicare Advantage bonus revenue across insurers.
Primarily US healthcare managed-care sentiment, with potential spillover to broader US defensive growth positioning.
Limited direct global impact, but it can influence US healthcare sector multiples via Medicare Advantage earnings outlook.
Counterpoint
Star ratings are backward-looking quality measures; near-term stock moves may overreact versus longer-term medical cost trends and execution on utilization management.
Key entities
- companyHumana
Medicare Advantage insurer that sharply improved 2027 star ratings outcomes after CMS released new quality data.
- companyAlignment Healthcare
Medicare Advantage insurer whose largest contract fell below the 4-star threshold for 2027, pressuring expected revenue.
- companyClover Health
Medicare Advantage insurer that received a 5-star contract for 2027 after previously challenging CMS calculations.
- regulatorCenters for Medicare and Medicaid Services (CMS)
Released updated Medicare Advantage quality data and changed the 2027 star ratings methodology.
